Key Highlights
● Adicet Bio (ACET) closed at $6.35 on Monday, down 29.60% from $9.02, a steep one-day fall for the clinical-stage biotech.
● The same day, the company released Phase 1 data for prula-cel in lupus that it described as positive.
● The company reported 54% DORIS remission among 22 evaluable patients and 50% complete renal response among evaluable lupus nephritis patients.
● Adicet plans pivotal study start-up activities in the fourth quarter of 2026, with a data update anticipated in mid-2027.
Adicet Bio (NASDAQ:ACET) closed at $6.35 on Monday, September 28, down 29.60% from $9.02, a steep one-day fall for a clinical-stage biotech. The move came on the same day the company released Phase 1 data for its cell therapy prula-cel, formerly ADI-001, in lupus, which it described as positive.
What the Company Reported
According to the release, 22 patients were evaluable for efficacy, 16 with lupus nephritis (a kidney complication of lupus) and six with lupus outside the kidneys, and all had at least six months of follow-up. A further two patients brought the number dosed and assessed for safety to 24, and 13 of them had at least 12 months of follow-up. Adicet reported DORIS remission, a standard measure of lupus disease control, in 54% of evaluable patients, and a complete renal response in 50% of evaluable nephritis patients. All patients discontinued immunosuppressants, according to the company.
On safety, the company reported no cytokine release syndrome of Grade 3 or higher, no ICANS cases, and infections in 54% of patients, with Grade 3 or higher infections in 8.3%. It said it plans to start up a pivotal study in the fourth quarter of 2026 and anticipates a data update in mid-2027.
Positive Data, Lower Stock
The company's release does not explain the share-price reaction, and no analyst commentary accounting for it was found in a check, so this article does not offer a cause. Share prices already reflect what investors expected, so data that a company calls positive do not always lift a stock. Small biotechs also trade on thin volumes, which can amplify moves in either direction.
Adicet develops cell therapies based on Gamma Delta T cells, a type of immune cell, including CAR-T candidates, in which immune cells are engineered to recognize a target. Lupus is a chronic autoimmune disease in which the immune system attacks healthy tissue, and cell therapy for autoimmune disease is one of the most closely watched areas in biotech. The Nasdaq Composite fell 248.34 points to 26,820.38 that day. Across the market, small caps lagged. The Russell 2000 fell 19.64 points, and lows swamped highs on the Nasdaq, 461 to 50.
What to Watch for Adicet Bio
The next milestones are the start-up of the pivotal study, which the company puts in the fourth quarter of 2026, and any discussion with the US Food and Drug Administration, since the release says a possible expansion to non-nephritis lupus depends on regulatory alignment. Fuller presentations of the data would also give investors more to work with, and the next Quarterly Report should update the cash position, which matters for a biotech funding a pivotal trial.
The week's data run from Tuesday's JOLTS and consumer confidence readings to Friday's jobs report, with PCE Inflation on Wednesday and ISM Manufacturing on Thursday. Health care held up as a sector on Monday, but that support did not extend to Adicet.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...